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ABSTRACT 
 
 
DEVELOPMENT OF NATURAL CYCLIC PEPTIDE INHIBITORS OF XRCC4/XLF 
INTERACTION FOR RADIO-SENSITIZATION OF BREAST TUMOR CELLS 
By Mohammed Al Mohaini, B.Sc. Pharm 
 A	  thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2012 
 
Advisor: Lawrence F. Povirk, Professor, Department of Pharmacology and Toxicology 
 
 
Breast cancer is the second leading cause of cancer death in women according to the 
American Cancer Society.  The standard treatment regimen for breast cancer involves ionizing 
radiation combined with surgery and chemotherapy.  Ionizing radiation induces a complex 
signaling response in cells resulting in either growth arrest, senescence or cell death, and the cell 
killing after exposure to radiation results largely from DNA double-strand breaks (DSBs).  There 
are two main mechanisms in mammalian cells responsible for repairing the DSBs; the primary 
mechanism is non-homologous end joining (NHEJ) and the secondary mechanism is 
homologous recombination (HRR).  Previous studies showed that breast tumor cells depend 
mainly on NHEJ for repairing induced DNA damage.  XRCC4 and XLF are two essential 
proteins in the NHEJ process.  The interaction between XRCC4 and XLF (also called 
Cernunnos) is responsible for stimulating ligase IV for rejoining DNA ends.  A single mutation 
on the XLF-binding interface of XRCC4 at M61, F106, M59 or D58 has been shown to disrupt 
	   xi	  
its interaction with XLF and thus inhibiting NHEJ.  Therefore, it is proposed that small natural 
cyclic peptides that bind to the XLF interface of XRCC4 near M61 and F106 can be identified 
through an mRNA display in vitro selection, and these peptides will inhibit NHEJ and thereby 
radiosensitize breast tumor cells. We have synthesized five DNA libraries that produced mRNA-
peptide fusions containing a trillion unique peptide sequences that will be used for the selection 
of peptide inhibitors of the XRCC4/XLF interaction, and we have verified their randomness. 
Tagged wild-type and mutant versions of the head domain of XRCC4 protein, containing the 
XLF binding site, were successfully purified, and the wild-type version was applied to initial 
stages of selection of inhibitory peptides by mRNA display. 
The percentage of the mRNA-peptide fusions that bound to the XRCC4157 after the first 
round was 2.1%.  The recovery after the second and third rounds was 1.14% and 2%, 
respectively. Results obtained thus far, although preliminary, suggest that the mRNA display 
method can be successfully applied to the XLF/XRCC4 interaction.   
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I. INTRODUCTION 
 
1.1 Breast Cancer 
Breast cancer in the United States is one of the most common cancers among women.  It 
is the second leading cause of cancer death in women, surpassed only by lung cancer (ACS, 
2012).  Also, breast cancer is the number one cancer killer in women aged 20-59 years old 
(Ahmedin et al., 2010).  There is a chance of one out eight women that will have an invasive 
breast cancer some time during their lives.  Also, one out of 36 women expected to die in 2012 
will do so as a result of breast cancer death.  
Breast cancer treatment requires multiple approaches.  The recommended treatment for 
most patients with “invasive” breast cancer is surgical removal of primary tumor, systemic 
chemotherapy and/or hormonal therapy as well as radiotherapy (Buchholz, 2009).  Breast 
irradiation is indicated for most patients who undergo breast-conserving surgery (lumpectomy).  
Also, radiation therapy is recommended after mastectomy for patients who are at high risk of 
developing recurrence (Shenkier et al., 2004).  The current treatment available for breast cancer 
has shown to be quite effective in suppressing the breast cancer growth and improving patients’ 
quality of life (Buchholz, 2009).  However, the risk of breast cancer recurrence is still not 
uncommon.  Recurrent breast cancer can occur months or years after the initial treatment.  Breast 
cancer recurrence can reappear as local recurrence at the original tumor site (invasive or 
noninvasive ipsilateral breast tumor recurrence), as regional recurrence in the axilla, chest 
muscle, internal mammary lymph nodes or supracavicular fossa lymph nodes, or as distant 
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recurrence (metastasis) in which the tumor cells leave the breast tissue and spread to other sites 
including bone, lungs, brain and other organs (Millar et al., 2009; Clarke et al., 2005; Bruce et 
al., 2006).  The prognosis of recurrence and metastatic breast cancer is generally poor and 
associated with high resistant to further treatment and reduced survival rate (Dean-Colomb & 
Esteva, 2008; Gonzalez-Angulo et al., 2007; Jameel et al., 2004).  
 
1.2 Radiation Therapy 
Radiation therapy is an essential part for the management of all stages of breast cancer 
(Tahernia et al., 2010).  In general, ionizing radiation causes chain reactions in cells leading to 
formation of multiple reactive free radicals causing damage in the DNA.  This stimulates a DNA 
damage response (DDR) that promotes multiple signal transduction cascades, which coordinate 
DNA repair, cell cycle progression and cell death modes to facilitate the accurate transmission of 
genetic material after DNA damage (Kesari et al., 2011).  The initiation of DDR starts by the 
activation of Mre11-Rad50-Nbs1 (MRN) complex and recruitment of ataxia-telangiectasia 
mutated (ATM) protein (D’Amous & Jackson, 2002; Shiloh, 2003).  Exposure of cells to 
therapeutic radiation can lead to different consequences including growth arrest, senescence, or 
one of multiple modes of cell death such as apoptosis, mitotic catastrophe, autophagy and 
necrosis (Abbott & Holt, 1999; K. Chu et al., 2004; Lehmann et al., 2007; Ullrich et al., 2008).  
Nevertheless, the tumoricidal activity of IR is found to be largely related to the formation of 
DSBs (Iliakis, 1991). 
There are two major mechanisms to repair DSBs; that are activated when DSBs occur 
including homologous recombination (HR) and non-homologous end joining (NHEJ) (Valerie & 
Povirk, 2003; Lieber, 2010). 
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1.3 Homologous Recombination (HRR) 
HR requires a sister chromatid to act as a template for repair; therefore, HR is only active 
in late S and G2 phases of the cell cycle and it is an error-free repair pathway (Helleday et al., 
2007).  HRR is highly efficient in repairing DSBs due to replication forks collapse, IR and inter-
strand cross-links (Sung & Klein, 2006).  In HRR, the DSB is first detected by the MRN 
complex, and the DNA ends subjected to 5ʹ3ʹ resection by CtIP, to generate a 3ʹ-single strand 
DNA (ssDNA) overhang (Li and Heyer, 2008).  Also, CtIP is known to be regulated by CDK 
and ATM (Chen et al, 2008; Li et al, 2000).  After that, replication protein A (RPA) binds to the 
3ʹ-ssDNA overhang to prevent premature strand invasion.  Then, different proteins including 
Rad52, BRCA2 and the Rad51 paralogues (Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3) 
are recruited to replace RPA by RAD51 (San et al., 2008).  This allows Rad51 to form a filament 
to invade a homologous sequence.  After that, DNA polymerase η is recruited to extend the 3ʹ-
DNA end which leads to capturing a second DSB end to form Holliday junctions; these junctions 
are resolved in a process involving different proteins resulting in crossover or non-crossover 
products (Helleday et al., 2007; Li & Heyer, 2008).   
 
1.4 Non-Homologous End Joining (NHEJ): 
NHEJ is the primary repair mechanism of DSBs, and it is the main repair mechanism in 
G0 and G1; even though it can function throughout the cell cycle (Rothkamm et al., 2003).  Also, 
NHEJ is essential mechanism in repairing DSBs due to V(D)J recombination (Jankovic et al., 
2007).  There are three main steps in the NHEJ pathway including the detection of DSBs, 
removal of the non-ligatable end groups and religation of the processed DNA ends (Williamson 
et al., 2009).  In other words, repairing DSBs by NHEJ pathway involves nuclease, polymerase, 
and ligase activities (Lieber, 2010).  Several studies have shown the importance of some proteins 
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in NHEJ pathway in human cells.  These proteins are Ku70/80 heterodimer (Ku), DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), DNA ligase IV, XRCC4 and XLF 
(Cernunnos) (Lieber, 2010).  Once DBSs occur, the first step in NHEJ is the detection of the 
breaks, which is achieved by Ku in which Ku heterodimer is recruited to the end of the DNA 
damage (Weterings & Chen, 2008).  When Ku binds, it acts as a scaffold to facilitate the binding 
of other NHEJ proteins.  Also, Ku recruits DNA-PKcs, a member of the phosphoatidylinositol-3 
kinase-like family of serine-threonine protein kinases (PIKKs), to form the DNA-PK complex 
which tethers the DNA ends together (Williamson et al., 2009).   Upon synapsis of the two DNA 
ends, DNA-PKcs phosphorylates itself in trans leading to its dissociation from the DNA ends 
which facilitates the access of downstream proteins, to the ends of the DSB (Weterings, 2007).  
After that, polymerases µ and λ are involved in gap filling (Mahaney et al., 2009), and the ends 
are ligated by the XRCC4-DNA ligase IV complex (X4L4), which is stimulated by an interaction 
between XLF and XRCC4.  Also, additional proteins may be required in a more complex 
subpathway of NHEJ including MRN complex, 53BP1, Artemis and the ATM kinase (reviewed 
in Valerie and Povirk, 2003). This subpathway may be neccesary for a subpopulation of more-
difficult-to repair DSBs, such as DSBs with heavily damaged termini, DSBs in heterochromatin, 
or DSB whose ends have become physically separated.  
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Figure	  1-­1:	  Nonhomologous	   end	   joining. The Ku 70/80 heterodimer binds to DNA DSB 
ends and recruits DNA-PKcs. This is followed by the recruitment of XLF:XRCC4:DNA ligase 
IV to the DNA ends which in turn leads to the synapsis of the two ends.  DNA-PK 
autophosphorylation causes a conformational change followed by its dissociation from the DNA 
ends.  This facilitates the access of downstream endonucleases proteins to process the DNA ends 
before gap filling by pol µ and λ and ligation that mediated by DNA ligase IV. Adapted from 
(Povirk, Valerie 2003). 
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1.5 The Choice of DSBs Repair Method 
Both DSB structure and chromatin complexities can affect the speed and choice of DSB 
repair pathway (Shibata et al., 2011).    When the DSBs occur in euchromatin DNA (EC-DNA) 
without DNA complexity, DSBs would be efficiently repaired with faster kinetics by NHEJ 
pathway independent to the cell cycle phase.  However, if DSBs occur in EC-DNA with high 
complexity, these DSBs would be repaired with slow kinetics in G1 and G2 phases by NHEJ, but 
NHEJ will stall in G2 phase allowing the DSBs to undergo resection to be repaired by HR.  
However, in case of chromatin complexity, the DSBs would be repaired by NHEJ with slow 
kinetics in G1 phase.  Again, in G2 phase, NHEJ is inefficient and will stall allowing resection of 
the DSBs that would be repaired by HR.  However, HR pathway can be switched to NHEJ in a 
heterochromatin DSBs if the CtIP dependent DSB end resection does not occur (Shibata et al., 
2011).   
 
1.6 The Choice of DSBs Repair Mechanism in Breast Cancer 
Breast cancers can be divided into two types; the first type known as sporadic breast 
cancer develops after conception and accounts for 90-95% of breast cancer cases. The other type 
of breast cancers is familial breast cancer due to mutated genes inherited from one’s parents.  It 
accounts for 5-10% of all breast cancers, and about 35 - 45% of familial breast cancer can be 
attributed to mutation in two different tumor suppressor genes known as BRCA1 and BRCA2 
(Rosen et al., 2003; Miki et al., 1994; Wooster et al., 1995).  Nevertheless, mutations in either of 
BRCA1 or BRCA2 occur occasionally in sporadic breast cancer (Futreal et al, 1994; Lancaster et 
al, 1996).   In addition to the role of mutated BRCA1 and 2 in predisposing individuals to breast 
cancer, these two proteins play an important role in protecting genome stability by responding to 
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DNA damage.  Particularly, these genes have been shown to be involved in DSBs repair and are 
mainly critical for efficient HR but appear to play only a minor role in NHEJ, although BRCA1 
may influence NHEJ fidelity (Gudmundsdottir & Ashworth, 2006; Nagaraju & Scully, 2007; H. 
Wang et al., 2001; Zhuang et al., 2006).  Many sporadic breast tumors show allelic loss (Johnson 
et al., 2002) and/or reduced expression (Birgisoittir et al, 2006; Jaspers et al., 2009; Yshikawa et 
al., 1999; Wilson et al., 1999) suggesting that those tumors would be more dependant on NHEJ.  
Conversely, breast tumor cells often show upregulation of receptors of the epidermal growth 
factor (EGFR) family (Johnson et al., 2006), which have been implicated in radioresistance 
(Contessa, Abell, Mikkelsen et al., 2006; Contessa, Abell, Valerie et al., 2006) and stimulation of 
NHEJ (Das et al., 2007).  Therefore, targeting NHEJ may selectively increase radiosensitivity of 
many breast tumor cells. 
 
1.7 XRCC4-XLF Interaction as a Target for Radiosensitization 
The XRCC4 gene was isolated by complementation of radiosensitivity, V(D)J 
recombination deficiency and DSB repair deficiency of the Chinese Hamster ovary derivative 
XR-1 (Li et al., 1995).  XRCC4 found to be associated with DNA ligase IV, and in vitro, the 
X4L4 complex is critical for broken DNA ends ligation through the NHEJ mechanism 
(Critchlow et al., 1997).  Also, XRCC4 in cells was found to stabilize the DNA Ligase IV 
(Bryans et al., 1999).  The ligation activity of X4L4 is stimulated by an interaction with XLF; the 
most recently discovered core protein of NHEJ (Ahnesorg et al., 2006; Buck et al., 2006).  XLF 
was identified initially as missing gene in a subset of severe combined immune 
deficiency (SCID) patients with characteristics of growth retardation, microcephaly, 
immunodeficiency, increased cellular radiosensitivity and a defective V(D)J recombination 
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(Buck et al., 2006).  Both proteins have no known enzymatic function, yet in mammalian cells, 
XRCC4-/- and XLF-/- genotype show increased sensitivity to ionizing radiation associated with 
severe defects in DSB repair (Giaccia et al., 1990; Zha et al., 2007).    
Crystal structure studies of XRCC4 and XLF show structural similarity of both proteins 
in which both of them form homodimers and have similar N-terminal head domains and long α 
helical tails (Li et al., 2008; Andres et al., 2007; Junop et al., 2000).  Mutagenesis studies of the 
head domains of XRCC4 and XLF found residues E55, D58, M61 and F106 of XRCC4, and 
R64, L65 and L115 of XLF as critical to XRCC4-XLF interaction (Ropars et al., 2011; Malivert 
et al., 2010).  Based on the crystal structures of XRCC4 and XLF, and based on mutagenesis 
analysis, it has been suggested that these two proteins could form filaments of alternating 
XRCC4-XLF dimers which could twist a DSB and help to align the ends (Andres et al., 2007).  
Regardless of the accuracy of the predicted filament formation between XRCC4 and XLF, the 
interaction between these proteins is essential for NHEJ.  Thus, this critical interaction should be 
susceptible to disruption by small peptides that bind this XLF-interacting region of XRCC4, and 
such disruption should severely suppress NHEJ. 
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  XLF	  XRCC4	  
Figure	  1-­2:	  Crystal	  structures	  of	  XRCC4	  and	  XLF. Both XRCC4 and XLF have two head 
domains and long α helix (Andres et al., 2007)  
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Figure 1- 3: Filaments of alternating XRCC4-XLF dimers.  Proposed filaments that 
show the formation of alternating filaments between XLF (orange) and XRCC4 (blue).  
The binding of XRCC4 to Ligase IV (yellow) is also indicated (Andres et al., 2007). 	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Figure 1-4: Interface of the XRCC41–157-XLF1–224 complex formed by the distal part of their 
N-terminal head domains. Residues involved in the interface between XRCC44 (cyan) and 
XLF (green) are shown in a stick representation.  Residues are labeled with “X” and “C” 
superscripts for X4 and Cernunnos (XLF), respectively. Dashed lines indicate inter- and intra-
molecular hydrogen bonds and salt bridges between side-chain atoms proposed from Rosetta 
modeling. (Taken from Ropars et al., 2011)	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1.8 mRNA Display 
mRNA display is an in vitro selection technology that can be used to synthesize libraries 
of mRNA-peptide fusions containing up to 10 trillion unique sequences (Roberts & Szostak, 
1997).  The main idea of this technology is the covalent attachment of the peptide chain to the 3ʹ 
end of its own mRNA template.  The process starts when the mRNA first becomes covalently 
attached at its 3ʹ end to a puromycin containing short DNA linker via a psoralen photo-crosslink.  
During an in vitro translation, when the ribosome reaches the crosslinked region and translation 
pauses, puromycin mimics the 3ʹ end of an incoming tRNA by entering the ribosome A-site and 
accepting the nascent peptide forming the covalent bond between the mRNA and the peptide it 
encodes.  Using a library of mRNAs transcribed from a synthetic DNA template, this process 
will create large collections of mRNA-peptide fusions.  The RNA portion of the mRNA-peptide 
fusions can be reverse-transcribed and PCR-amplified, which allows for the identification of the 
functional peptide by DNA sequencing.  Several rounds of selection and amplification can be 
carried out in order to allow for an enrichment of unique sequences with the required properties.  
mRNA display has many applications.  For example, this method has been used to 
identify molecules that bound to TNF-α with a dissociation constant of 20 pM (Xu et al., 2002).  
Also, this technique was used to select molecules that bind to phosphorylated IkBα with an 
affinity of 18 nM (Olson et al., 2008).  Moreover, mRNA display was helpful in selecting Bcl-xL 
inhibitor with an IC50 of 0.9 µM (Matsumura et al., 2010).  In addition, an inhibitor with an IC50 
of 2-5 nM has been identified by mRNA display to inhibit a protein-ligand interaction between 
VEGF and its receptor Flt-1 with 800 Å2 of buried interfacial surface area (Getmanova et al., 
2006; Wiesmann et al., 1997).  Also, the mRNA display has been used to develop two unnatural 
and one natural peptide inhibitors of thrombin with Kd in nanomolar range (Schilppe et al., 
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2012).  The unnatural peptide inhibitors have Kd of 4.5 and 20 nM while the natural one has a Kd 
of 1.5 nM.   
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II. METHODS 
 
2.1 Production of Wild Type GST- XRCC41-157, Double Mutant GST - XRCC41-157 (M61R 
and F106E) and Double Mutant Trx - XRCC41-157 Protein 
 
2.1.1 Construction of Wild Type XRCC41-157 
Wild type truncated XRCC41-157 was amplified by PCR from the full-length XRCC4 
sequence (366 amino acids) on pFLAG-CMV-2 (K. Jones, 2005) using FastStart PCR Master 
mix (Roche) and the primers 5ʹ-GGATCCATGGAGAGAAAAATAAGCAGAATCCACC-3ʹ 
and 5ʹ-CTCGAGTCAGTGATGATGATGATGATGATCATTCCAATCTCTCAGAAGCCTT-
TC-3ʹ with insertion of BamHI restriction site at the N terminus and an XhoI site following the  
6xHis tag at the C terminus, immediately following residue 157.  The PCR reaction contained (5 
ng pFLAG-CMV-2 - XRCC4 plasmid), 1X PCR master mix (2X: 50 units/mL of Taq DNA 
polymerase supplied in a proprietary reaction buffer (pH 8.5), 400µM dATP, 400µM dGTP, 
400µM dCTP, 400µM dTTP, 3mM MgCl2) and 0.5 µM of each primer.  The PCR reaction 
carried out with an initial heating of 94oC for 5 minutes followed by 5 cylces of 94oC for 10 
seconds (denature), 50oC for 20 seconds (annealing) and 72oC for 1 minute (extension) followed 
by 35 cylces of 94oC for 10 seconds (denature), 58oC for 20 seconds (annealing) and 72oC for 1 
minute (extension) with a final extension of 72oC for 7 minutes.  The XRCC41-157   PCR product 
amplified was mixed with sample buffer and resolved on a 1% agarose gel containing ethidium 
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bromide for visualization using UV. The XRCC41-157 PCR product was cut from the gel and 
purified by QIAquick Gel Extraction Kit from QIAGEN. 
 
2.1.2 Insertion of XRCC41-157 into the pGEX-4T-1 Expression Plasmid Vector 
First, the pGEX-4T-1 expression vector (GE Healthcare) for expression of N-terminal 
GST protein was digested with BamHI for 2 hours at 37oC; followed by 2 hours digestion at 
37oC with XhoI and 30 minutes at 37oC with antarctic phosphatase (New England BioLabs Inc.).  
After that, the digested pGEX-4T-1 was resolved on a 1% agarose gel and purified by QIAquick 
Gel Extraction Kit.  Also, XRCC41-157 fragment was digested with BamHI and XhoI for 2 hours 
at 37oC and purified.  The ligation reaction was performed using a 10-fold molar excess of 
XRCC4 insert DNA over vector.  Approximately 50 ng of pGEX-4T-1 was used and the amount 
of insert DNA needed was 48 ng.  XRCC41-157 and pGEX-4T-1 were ligated together at 16oC 
overnight using T4 DNA ligase and its supplied buffer (Roche, Indianapolis, IN) in a final 
ligation volume of 10 µL.  Fifty µL of E. coli competent (DH5 α) bacterial cells (Strategene) 
were transformed by heat shock with 5 µL out of 10 µL of the ligated DNA.  The DNA and E. 
coli cells were mixed and placed on ice for 30 minutes, placed in a 42oC water bath for 45 
seconds and placed on ice for 2 minutes.  Following 2 minutes on ice, 1000 µL of LB broth was 
added followed by 1 hour incubation with agitation at 37oC.  In order to grow a mix of colonies, 
following incubation, 10 µL, 100 µL, 200 µL of the transformation mix were spread on LB agar 
plates containing 100 µg/ml ampicillin and incubated at 37oC overnight.  pGEX-4T-1 contains 
an ampicillin resistance gene.  Therefore, E. coli colonies that contain pGEX-4T-1 should grow 
in the presence of ampicillin.  Individual colonies that grew on agar plates were selected using a 
sterile toothpick and each colony was added to 5 mL of LB medium containing 100 µg/ml 
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ampicillin and incubated at 37oC overnight with gentle agitation.  Plasmid DNA from individual 
colonies were isolated using mini-prep plasmid DNA isolation kit from QIAGEN.  Confirmation 
that the plasmid DNA, isolated from the colonies, contained XRCC41-157 and pGEX-4T-1 was 
achieved by digesting the purified colonies with BamHI and XhoI restriction enzymes and 
compared the size on a 1% agarose gel.  Furthermore, confirmation was achieved by DNA 
sequencing.    
 
2.1.3 Construction of Double Mutants XRCC41-157 (M61R and F106E) 
Double-mutants of XRCC41-157 (M61R and F106E) were generated directly from the wild 
type XRCC41-157-pGEX-4T-1 plasmid using the QuickChange site-directed mutagenesis kit 
(Stratagene), and primers that determined by the QuickChange Primer Design Program 
(Stratagene).  For M61R: 5ʹ-CCAAGAAGCTGATGACATGGCAAGGGAAAAAGGGAAAT-
ATG-3ʹ and 5ʹ-CATATTTCCCTTTTTCCCTTGCCATGTCATCAGCTTCTTGG-3’.  For 
F106E: 5ʹ-ATTTCTTCTTTGAGAAAAACCTGAAAGATGTCTCAGAGAGACTTGGTTCCT-
TCAAC-3ʹ and 5ʹ-GTTGAAGGAACCAAGTCTCTCTGAGACATCTTTCAGGTTTTTCTCA-
AAGAAGAAAT-3ʹ.  The mutated residues are highlighted in which the methionine (ATG) was 
mutated to arginine (AGG) and the phenylalanine (TTC) was mutated to glutamic acid (GAG).   
Then, the double-mutant plasmid DNA was transformed into E. coli.  Transformation of E. coli 
cells with the double-mutant DNA was performed as previously described.  Colony selection and 
verification was also performed as previously described.  
 
2.1.4 Insertion of Double-Mutants XRCC41-157 (M61R and F106E) Gene into pET-32XT 
Expression Vector 
The double-mutant XRCC41-157 (M61R and F106E) was also transformed into pET-32XT 
expression vector that has thioredoxin tag at its N-terminus.  pET-32XT is a modified vector 
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from pET-32a in which the original thrombin cleavage site encoded by the pET-32a vector was 
removed by site-directed mutagenesis (Arg  Gln) (Cai et al., 2003).  pET-32XT has BamHI 
and XhoI restriction sites.  First, both double-mutant pGEX-4T-1- XRCC41-157 plasmid and pET-
32XT-Smad6 MH2 domain plasmid were digested with BamHI and XhoI restriction sites for 2 
hours at 37oC.  Then, XRCC41-157 was ligated to pET-32XT as described (see 2.1.2).  
Transformation of E. coli cells, colony selection and verification was also performed as 
previously described.  
 
2.1.5 Production of Wild-Type and Double-Mutant XRCC41-157 Proteins 
Wild type and mutant XRCC41-157 plasmids were expressed in E. coli BL21 (DE3) 
competent cells and induced using an autoinduction protocol for protein production (F.W. 
Studier, 2005).  First, single colonies of the plasmids harboring wild-type or mutant XRCC41-157 
were grown overnight at 37oC with agitation in 5 mL LB medium containing 100 µg/ml 
ampicillin.  Then, 1 ml of the overnight cultures was transferred into four 2 L flasks containing 
500 mL ZYM-5052 medium (each 500 mL culture contains 5 gm tryptone, 2.5 gm yeast, 10 mL 
of 50XM solution, 10 mL of 50X5052 solution, 500 µL of 1000X trace metals and 500 µLof 100 
µg/ml ampicillin).  The four cultures were inoculated at 37oC with agitation for 3-4 hours until 
visible turbidity can be seen.  Then, the cultures were left to grow at 20oC overnight.  After that, 
time course of optical density (600 nm) measurements were taken of the four cultures until they 
reached saturation.  Then, the cells centrifuged at 4000 rpm and 4°C for 30 minutes, and the dry 
pellets were stored at – 20oC. 
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Stock solutions: 
50XM  1000X Trace metals 
   
25 mM Na2HPO4  50 mM FeCl3 
25mM KH2PO4   20 mM CaCl2 
50 mM NH4Cl  10 mM MnCl2 
5 mM Na2SO4  10 mM ZnSO4 
  2 mM CoCl2 
50X5052   2 mM CuCl2 
  2 mM NiCl2 
0.5% Glycerol (w/v) 2 mM Na2MoO4 
0.05% Glucose  2 mM Na2SeO3 
0.2% α lactose 
  
2 mM H3BO3 in 60 mM HCl 
500X MgSo4    
   
2 mM MgSO4   
 
2.1.6 Ni-NTA Purification 
Cell pellets were left to thaw in ice and the pellet in each bottle was resuspended in 5 ml 
of freshly prepared Basic Buffer N (50 nM phosphate pH 8, 10% glycerol, 5 mM fresh 2-
mercaptoethanol (BME), 20 mM imidazole and 0.5 M NaCl) and 150 µL His compatible 
protease inhibitor (Merck, EMD).  After that, the cells were transferred into a 50 mL centrifugal 
tube and sonicated 4X 45 seconds on 30% power (Sonicator from Ultrasonic Inc.).  The lysed 
cells were diluted with 20 mL Basic Buffer N and centrifuged for 15 minutes at 15000 rpm at 
4°C.  Then, the supernatants were collected and mixed with 4 mL Ni-NTA resin (QIAGEN) and 
gently stirred for 1 hour at 4°C.   After that, the flow through was collected and the resin washed 
with 20 mL of Basic Buffer N.  The protein was eluted 6 times and each time was with 2 mL of 
Ni-NTA elution buffer (50 mM NaH2PO4, 300 mM NaCl and 250 mM imidazole; pH 8).   All 
six fractions were analyzed by SDS-PAGE electrophoresis.  Then, the elutions were combined 
and dialyzed in a 3-12 mL volume Slide-A-Lyzer dialysis cassette for 4-6 hours at 4°C against 1 
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L enzyme dialysis buffer (50 mM HEPES-KOH, pH 7.6, 100 mM KCl, 10 mM MgCl2, 5 mM 
fresh BME, 30% glycerol).  The dialysis buffer then was changed and left overnight.  The 
overnight-dialyzed protein solutions were collected and the OD280 was measured using a 
spectrophotometer.  Then, the protein concentration was calculated and the protein was divided 
in small aliquots and stored at – 80°C.    
 
2.1.7 Thrombin Cleavage of GST- XRCC4157 DM Protein 
 The cleavage of the GST moiety from the GST-XRCC4157 DM was carried out using 
thrombin (GE Healthcare).  The concentration of the thrombin is 1 U/µL and each unit can 
cleave > 90% of 100 µg of fusion protein in 16 hours at 22°C.  The protein was dialyzed 
overnight with 1X PBS buffer (140 mM NaCl, 2.7 mM KCL, 10 mM Na2HPO4, 1.8mM 
KH2PO4; pH 7.4).  The dialyzed protein was collected and the concentration was measured.  
Then, one mg of protein was incubated with 1 or 2 units of thrombin.  The reaction was mixed 
gently at room temperature and 10 µL was taken after 2, 4, 16 and 18 hours.   The protease 
activity was stopped with 1 µL of His-compatible protease inhibitor cocktail (Calbiochem) and 
saved at -20°C until use.  The results were checked on 12% SDS-PAGE.    
 
2.2 mRNA Display and In Vitro Selection 
2.2.1 DNA library Synthesis 
Five different DNA libraries have been synthesized (by Dr. Hartman) and used in the 
selection process.  Briefly, each library encodes a fixed cysteine at the N-terminus and another 
cysteine after 2, 4, 6, 8, or 10 random amino acids in order to produce different cyclic sizes of 
peptides.  The DNA sequence of the random library is: 
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TAATACGACTCACTATAGGGTTAACTTTACTAAGGAGGACAGCTAAATGTGCNNSNN
SNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSGGTAGCGGCTCCTTAGGCCACCAT
CACCATCACCACCGGCTATAGGTAGCTAG 
The detailed sequence composition of each library is as follows:  
1- TAATACGACTCACTATA: T7 promoter, followed by GGG with the first “G” as the 
transcription start.  
2- TTAACTTTAG: Epsilon enhancer.  
3- TAAGGAGG: Shine-Dalgarno sequence, also known as the ribosome binding site.  
4- ACAGCTAA: the Spacer between ribosome binding site and the start codon, with “AA” at 
end. 
5- ATGTGCNNS’sTGCNNS’s: translation start codon for methionine (ATG) and the codon for 
the fixed cysteine (TGC), followed by a mix of random NNS codons and another fixed cysteine 
at the site indicated above.  N denotes A, T, C, or G, and S denotes G, or C.  The translated 
peptides have the sequence of MCX2CX10GSGSLGHis6, MCX4CX8GSGSLGHis6, 
MCX6CX6GSGSLGHis6, MCX8CX4GSGSLGHis6, or MCX10CX2GSGSLGHis6, where X 
can be one of the natural amino acids.  
6- GGCTCCGGTAGCTTAGGC: codons for GlySerGlySer- LeuGly, the flexible linker with 
two out-of-frame stop codons.  
7- CACCATCACCATCAC: codons for His5 tag. The sixth His of His6 tag is in the following 
sequence.  
8- CACCGGCTAT: hybridization region for the Psoralen crosslinker (XL-PSO oligonucleotide, 
see below). The CAC encodes the sixth His of the intact His6 tag.  
9- AGGTAGCTAG: 3’ -UTR to allow those non-crosslinked peptides to release at the in-frame 
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TAG stop codons.  
 
2.2.2 PCR Amplification of Library DNA 
The DNA libraries were synthesized in reverse orientation.  For example, CTAGCTACCTATA-
GCCGGTGGTGATGGTGATGGTGGCCTAAGGAGCCGCTACCSNNSNNSNNSNNSNNSN
NSNNSNNSNNSNNSNNSNNSNNGCACATTTAGCTGTCCTCCTTAGTAAAGTTAACCCT
ATAGTGAGTCGTATTA.  Then, the DNA libraries were amplified by PCR using the following 
primers 5ʹ-TAATACGACTCACTATAGGGTTAACTTTACTAAGGAGGACAG-3ʹ and the 5ʹ-
CTAGCT-ACCTATAGCCGGTGGTGATGGTGATGGTGGCCTAAGGAGCCGCTACC-3ʹ.  
Each PCR reaction contained 12 nM of DNA library, 0.5 µM of each primer, 1X ThermoPol 
buffer, 100 µM of dNTP’s and 5 U of Taq polymerase.  The PCR reaction started by an initial 
heating of 94°C for 2 minutes followed by 18 cycles of 94°C for 15 seconds, 60°C for 30 
seconds, and 72°C for 45 seconds followed by 72°C for 5 minutes.  PCR product amplified was 
mixed with sample buffer and resolved on a 2% agarose gel containing ethidium bromide for 
visualization using UV.  PCR product was cut from the gel and gel purified by QIAquick Gel 
Extraction Kit from QIAGEN. 
 
2.2.3 StrataClone Cloning and Sequencing 
The PCR product was ligated to StrataClone vector (Stratagene).  The ligation product 
was transformed into StrataClone SoloPack competent cells following the StrataClone PCR 
Cloning Kit from Stratagene.  After that, the transformation product was plated onto LB plates 
containing 20 mg/ml kanamycin and the plates were incubated overnight at 37°C.  Then, 96 
single colonies were selected and sent for sequencing to ensure that the libraries were 
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synthesized as designed. 
 
2.2.4 Transcription and Purification of mRNA 
 Each library was transcribed by setting up a 1 ml transcription reaction that contains 0.1 
µM DNA library, 0.6 µM T7 primer, 40 mM/0.1% Tris/Triton solution, 2.5 mM spermidine, 25 
mM MgCl2, 10 mM DTT, 5 mM CTP, 5 mM UTP, 5 mM ATP, 9 mM GTP, 0.2 U/µl RNase 
inhibitor, 1 U/µl inorganic pyrophosphatase and 1 U/µl T7 RNA polymerase (MA & Hartman, 
2012).  Then, the reaction was incubated overnight at 37°C in an incubator chamber.  After that, 
the transcription reaction was removed from the incubator and 50 µL of Turbo DNase 
(Invitrogen) was added and the reaction was incubated for 15 minutes at 37°C.  After incubation, 
7.5 M urea was added and mixed well and the reaction was loaded on Urea PAGE by setting up a 
large 65 SequaGel (20 cm X 20 cm) on an Owl P10DS Dual Gel System. The gel was pre-run for 
20–30 min by using constant power at 25 W supplied by EC Apparatus electrophoresis power 
supply EC 600.  Then, the urea was flushed out from well and the sample was loaded.  The gel 
was run at constant power of 25 W for 60-90 minutes until the bromophenol blue reaches the 
bottom of the gel.  After that, the gel was transferred from the glass plates to Saran wrap on both 
sides and the mRNA band was visualized by UV shadowing and the band cut out with a fresh 
razor blade. 
After that, the mRNA was eluted by using the Whatman Elutrap electroelution System. 
First, the gel slice was put into the chamber, and mashed into small pieces and the chamber filled 
with 0.5X TBE buffer until the gel is covered.  The electroelution was run for 2 h at 300 V on a 
Bio-Rad PowerPac basic power supply.  At the end of running, the electrodes switched and run 
backwards for 1 min at 300 V.  Then, the solution between membranes was collected and ethanol 
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precipitated with 0.1 volume of 3 M KOAc and 3 volumes of 100% ethanol.  The sample was 
mixed well and frozen at −20°C for 30 minutes.  After that, the sample was centrifuged at 16,000 
Xg for 20 minutes at 4°C.  The supernatant was discarded and the pellet washed with 500 µL of 
70% ethanol and centrifuged again at 16,000 xg for 1 min.  The supernatant was discarded and 
the pellet air-dried for 5–10 min at room temperature.  The mRNA was dissolved in ddH2O and 
an absorbance at 260 nm was measured on a spectrophotometer.  The concentration was 
calculated by using the online software Oligonucleotide Properties Calculator 
(http://www.unc.edu/~cail/biotool/oligo/index.htmL).  Then, the mRNA was stored at -20°C. 
 
2.2.5 Psoralen Photo-Crosslinking 
The five mRNA libraries were mixed together with a final concentration of 2 µM in order 
to be photo-crosslinked with an XL-PSO oligonucleotide.  The sequence of the XL-PSO 
oligonucleotide is 5ʹ-PsoC6-(UAGCCGGUG)2ʹ-OMe-15xA-2xSpacer9-ACC-Puro-3ʹ. Spacer9 is 
triethyleneglycol (TEG) phosphoramidites and it is used to tether 5′-dCdC-puromycin to the 3′-
end.  The Psoralen photo-crosslinking reaction contains 20 mM HEPES-KOH, pH 7.6, 7.5 µM 
XL oligo, 100 mM KCl, 1 mM spermidine, 1 mM EDTA and the mixture of the mRNA libraries.  
The reaction was mixed well and transferred into PCR tubes with 100 µl in each tube.  The PCR 
tubes were placed in a PCR machine, heated to 70°C for 5 min, then cooled to 25°C over 5 min 
(0.1°C/s).  After this, each sample was transferred to a crosslink plate, 100 µL per well.  A 365 
nm UV lamp was used to irradiate the plate for 20 minutes at 4°C.  The samples were collected 
in 1.5 ml eppendorf tube and ethanol precipitated as previously described.  The pellet was 
resuspended in the required volume.   
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2.2.6 In vitro translation 
A 5 ml translation reaction was prepared, which contained 8 mM putrescine, 1mM 
spermidine, 5 mM potassium phosphate, 95 mM potassium chloride, 5 mM ammonium chloride, 
5 mM magnesium acetate, 0.5 mM calcium chloride, 1mM dithiothreitol, 1 µg/ml inorganic 
pyrophosphatase, 4 µg/ml creatine kinase, 1.1 µg/mL nucleotide diphosphate kinase, 30 µM 
(6R,S)-5,10-formyl-5,6,7,8-tetrahydrofolic acid, 93 µg/mL myokinase, 10 mM creatine 
phosphate, 2 mM ATP, 2mM GTP, 2.4 mg/ml E. coli total tRNA, 0.2 µM MTF, 1.0 µM IF1, 0.3 
µM IF2, 0.7 µM IF3, 3.2 µM EF-Tu, 0.6 µM EF-Ts, 0.5 µM EF-G, 0.3 µM RF1, 0.4 µM RF3, 
0.1 µM RRF and 0.5 µM ribosomes. In addition, the reaction contained 18 natural amino acids 
(200 µM each), 10 µM cysteine, 10 µM methionine and 20 aminoacyl tRNA synthetases (0.1 
µM MetRS, 0.3 µM LeuRS, 0.6 µM GluRS, 0.2 µM ProRS, 1.0 µM GlnRS, 1.0 µM HisRS, 0.25 
µM PheRS A294G, 1.5 µM TrpRS, 0.2 µM SerRS, 0.2 µM IleRS, 0.4 µM ThrRS, 0.6 µM 
AsnRS, 0.6 µM AspRS, 0.5 µM TyrRS, 0.5 µM LysRS, 0.4 µM ArgRS, 0.2 µM ValRS, 0.2 µM 
AlaRS, 0.5 µM CysRS, and 0.06 µM GlyRS).  0.3 µM of 35S-Met is added to isotopically label 
the peptides.  The translation mix was incubated for 15 minutes at 37°C.  Then, the 2 µM photo-
crosslinked mRNA was added to the translation mix and incubated for 1 hour at 37°C.  After 
that, the translation reaction was quenched with 550 mM KCl and 50 mM MgCl2 followed by an 
incubation for 90 minutes at 37°C.  Then, the translation reaction was chilled overnight at -80°C. 
 
2.2.7 Oligo(dT) Purification and Cyclization 
The goal of oligo(dT) purification and cyclization is to remove all non photo-crosslinked 
mRNA-peptide fusions and to produce cyclic peptides at the same time (Figure 2-1).  The 
translation reaction was thawed and vortexed and 5 µL removed for scintillation counting to 
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determine the total radioactivity of 35S-Met added to the translation reaction.  Then, five 100 mg 
Oligo(dT)-cellulose Type 7 (GE Healthcare) were added to five 20 mL Bio-Rad Econo-Pac 
columns (BioRad) and rinsed once with 5 ml ddH2O to swell cellulose and twice with oligo(dT) 
binding buffer (20 mM Tris–HCl, pH 7.8, 10 mM EDTA, 1 M NaCl, 0.2% Triton X-100. Add 
0.5 mM fresh TCEP).  Then, each one ml of the translation reaction was added to one column 
and the reaction was brought up to 4 mL with the binding buffer.  The columns were placed on a 
rocking platform shaker in 4°C cold room and shook for 30 min.  After that, the flow through 
was removed and the reaction was rinsed twice with the oligo(dT) binding buffer.  Then, 4 mL of 
cyclization buffer (20 mM Tris–HCl, pH 7.8, 0.66 M NaCl, 3 mM α,αʹ′ -dibromo- m -xylene 
(Sigma-Aldrich/Fluka), 33% acetonitrile (v/v), 0.5 mM fresh TCEP) was added to each reaction 
and rocked for 30 minutes at room temperature.  Then, the flow through was removed and each 
column was washed twice with 4.5 mL olido(dT) wash buffer (20 mM Tris–HCl, pH 7.8, 0.3 M 
NaCl, 0.1% Triton X-100); first wash was with 5 mM fresh BME and the other wash was with 
0.5 mM fresh TCEP.  Then, the columns were eluted 8 times with ddH2O and filtered to remove 
out residual Oligo(dT)-cellulose in the fusion solution.  One µL of each eluent was counted in a 
scintillation counter and the fractions with significant radioactivity were combined and ethanol 
precipitated using 0.3 volume of 3 M KOAc, pH 5.2, 0.002 volume of glycogen (5mg/mL) 
(Applied Biosystems), and 3 volume of 100% ethanol.  Then, the pmole amount of the mRNA-
peptide fusion was calculated based on the scintillation counts and the pellet re-dissolved in 
ddH2O so that the final concentration of the fusion is 100 nM (0.1 pmole/µL). 
 
2.2.8 Reverse Transcription  
The goal of reverse transcription (RT) is to convert the single-stranded mRNA portions 
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of the fusions to heteroduplex of RNA/DNA in order to eliminate any unwanted RNA secondary 
structures and render the nucleic acid portion of the fusion more stable.  The RT reaction was 
carried out following the Superscript III First Strand Synthesis Kit (Invitrogen).  In a 
microcentrifuge tube, the 100 nM mRNA-peptide fusions was added to 0.5 mM dNTPs and 0.5 
µM RT-primer TTTTTTTTTTTTTTTGTGATGGTGATGGTGGCCTAAGC. The tube was 
incubated for 5 minutes at 65 °C in a heating block. After five minutes, the tube was immediately 
placed on ice and incubated for at least 1 minute.  Then, the following reagents were added in a 
final concentration of 5 mM MgCl2 , 1 mM DTT, 2 U/ µL RNaseOUT (Invitrogen), 5 U/ µL 
Superscript III (Invitrogen).  The RT reaction was incubated for 15 minutes at 55°C for 
elongation, then 15 minutes at 70°C to inactivate the Superscript III.  At the end of the RT 
reaction, 0.5 µL of each RT reaction was counted in a scintillation counter in order to calculate 
how much of mRNA-peptide fusions was recovered.   
 
2.2.9 Ni-NTA Purification 
Ni-NTA purification was performed in order to remove any truncated peptide fusions 
(Figure 2-2).  The following buffers were prepared for Ni-NTA purification under native 
condition: Denaturing	  Binding	  buffer,	  pH	  8	   Wash buffer, pH 8  Elution buffer, pH 8  
   100 mM NaH2PO4 
   10 mM Tris HCl 
   6 M guanidinium HCL 
   0.2% Triton X-100 
   5 mM BME (fresh) 
   100 mM NaH2PO4 
   300mM NaCl 
   0.2% Triton X-100 
   5 mM BME (fresh) 
   50 mM NaH2PO4 
   300mM NaCl 
   250mM imidazole 
   0.2% Triton X-100 
   5 mM BME (fresh) 
First, 100 µl of Ni-NTA agarose was added into spin filter tube.  Then, the RT reaction 
was diluted 5 fold with the Ni-NTA denaturing binding buffer and transferred into filter tube.   
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The peptide fusion was bound to the Ni-NTA for one hour at 4ºC in a tumbler in a cold room.  
After that, the flow through was removed by centrifuging at 5900 rpm for 1 minute.  The resin 
was washed 3 times with Ni-NTA wash buffer and centrifuged at each time.  Then, the peptide 
fusion was eluted 6 times with portions of 50 µL Ni-NTA elution buffer and 0.5 µL of each 
eluent was counted in a scintillation counter to measure how much of mRNA-peptide fusions 
recovered.  All eluents with high counts were combined and dialyzed against 1 L pre-cooled 
selection buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 4 mM MgCl2, 0.25% Triton X-100, 
0.1 mg/ml BSA).  The overnight-dialyzed peptide fusions were collected and 1 µL was counted 
in a scintillation counter. 
 
2.2.10 In Vitro Selection 
The selection process started by an overnight incubation of two proteins with Pierce 
Magnetic Glutathione beads (Thermo Fisher Scientific).  The first sample contains GST protein 
only or GST-XRCC4157 DM for negative selection (pre-clearing) (Figure 2-3 and Figure 2-4) and 
the second sample contains GST-XRCC4157 fusion for selection (Figure 2-5).  50 µL of Pierce 
Magnetic Glutathione beads per 1 mL translation reaction was transferred into two 1.5 mL 
eppendorf tubes and washed three times with 400 µL GST beads wash buffer (125 mM Tris–
HCl, pH 8.0, 150 mM NaCl); each time the magnetic beads were mixed gently and the 
supernatant was removed by using Magnetic separation stand (Invitrogen).  130 µg of each 
protein was mixed with 400 µL GST beads wash buffer and transferred to the tubes with 
magnetic beads and incubated at 4°C for overnight with rotation on a tube rotator.  In the next 
day, the magnetic beads with GST protein were pelleted briefly and the supernatant was removed 
using the magnetic stand.   The beads were washed twice with 400 µL GST beads wash buffer 
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and once with 400 µL selection buffer.  Then, the dialyzed mRNA-peptide fusions from the 
previous step were added to the tube at a final concentration of 0.1 mg/mL BSA was added.  The 
tube was incubated at 4°C for 2 hours with rotation.  After that, the supernatant was collected 
and the beads washed three times with 200 µL selection buffer. The beads from this step and 10 
µL from the supernatant and washes were counted in a scintillation counter. Then, the remaining 
of the supernatant and the three washes were transferred to the other tube that contains the GST- 
XRCC4157 fusion.  The tube was incubated at 4°C for 2 hours with rotation. Then, the 
supernatant was removed and the beads were washed three times with 400 µL of the selection 
buffer. Then, the beads were suspended in 100 µL of the selection buffer and 5 µL was counted 
in a scintillation counter. After that, the mRNA-peptide fusions that attached to the GST-
XRCC4157 were amplified by PCR directly from the beads as described bellow. 
 
2.2.11 PCR Amplification of Selected Fusions 
The PCR reaction was carried out directly from the beads.  First, a test of 100 µL PCR 
reaction was done with 5 µL of the suspended beads in order to find the optimum conditions for 
PCR.  The PCR reaction was performed as previously described with the following primes 5ʹ-
TAATACGACTCACTATAGGGTTAACTTTACTAAGGAGGACAGCTAAATG-3ʹ and the 5ʹ-
CTAGCTACCTATAGCCGGTGGTGATGGTGATGGT-GGCCTAAGGAGCCGCTACC-3ʹ.  
Starting in cycle 14, 5 µL was taken out of the PCR tube after the elongation step (step 4, at 
72°C).  The PCR machine was paused at 44 seconds of this step and 5 µL was taken from the 
PCR reaction. This was done for even numbered PCR cycles 14-32.  The PCR product was 
checked on 2% agarose gel and the intensity of DNA bands was analyzed to find out the 
optimum conditions of the PCR.  Then, large-scale PCR was set up using multiple PCR tubes 
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and all suspended beads were used to amplify the selected fusions.   After PCR, the reaction 
mixtures were combined and an equal volume phenol:chloroform:isoamyl alcohol (25:24:1) 
(Sigma-Aldrich) was added.  The sample was vortexed and centrifuged at 4000 rpm for 2 
minutes in a cold room.  The upper layer was transferred to a new tube and an equal volume of 
CHCl3 was added to the tube and span down again.  The aqueous layer was transferred to new 
tube and ethanol precipitated as previously described.  The resulting precipitate was dissolved 
into a final volume of 100 µL ddH20, and passed over a NAP-5 column (GE Healthcare) to de-
salt.  The final volume from NAP-5 was 500 µL.  This was the template for the next round of 
selection. 
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Figure 2-1: In vitro transcription, photo cross-linking and in vitro translation 
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Figure 2-2: mRNA-Peptide Fusions Purification Steps. 
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Figure 2-3: Pre-Clearing (Negative Selection) with GST Protein Only.  We will do pre-
clearing with GST protein only in the first three rounds.  
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Figure 2-4: Pre-Clearing (Negative Selection) with GST-XRCC4157 Protein. We will use 
GST-XRCC4157 DM for pre-clearing in advanced rounds.  This will increase the stringency. 
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Figure 2-5: In vitro Selection.  The mRNA-peptide fusions that bound to the XLF interface of 
XRCC4 will be amplified directly from the beads in the first four rounds.  However, in advanced 
rounds, the selective inhibitors will be eluted with adding excess of Trx-XRCC4157 DM. 
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III. RESULTS 
 
3.1 Cloning of Wild Type XRCC4157 into pGEX-4T-1 Vector and Production of WT GST- 
XRCC4157 Protein 
As described in the introduction, the main aim of this study is to find peptide inhibitors of 
the XRCC4-XLF interaction in order to increase radiosensitivity of breast cancer cells.  
Therefore, we first cloned the WT and DM XRCC4 into expression vectors and produced GST 
and Thioredoxin tagged XRCC4 to be used in the selection of such peptides from a library.  
Previous studies showed that the interaction between XRCC4 and XLF occurs through 
the head domains (Ropars et al., 2011; Malivert et al., 2010).   Therefore, a truncated XRCC4157 
gene was produced from a full length XRCC4336 (Figure 3-1).  The process started by PCR 
amplification of a XRCC4157 fragment from the pFLAG-CMV-2 - XRCC4336 plasmid.   The 
XRCC4157 fragment was separated on a 1% agarose gel (Figure 3-2).  The band corresponding to 
our XRCC4157 fragment was on 504 bp (471 bp for the 157 residues of XRCC4 in addition to 33 
bp of BamHI and XhoI restriction sites, stop codon site and 6xHis that we added on our 
fragment).  Therefore, the XRCC4157 fragment (504 bp) was purified from the gel using 
QIAquick Gel Extraction Kit and cut with BamHI and XhoI restriction enzymes to prepare for 
ligation into the pGEX-4T-1 vector. The pGEX-4T-1 is an expression vector that contains a GST 
tag at its N-terminus in addition to a multiple cloning site where XRCC4157 gene can be cloned.  
The purpose of cloning XRCC4157 into this vector is to be able to immobilize the protein on 
magnetic beads during the selection process.  Therefore, pGEX-4T-1 vector was first cut with 
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BamHI and XhoI restriction enzymes following by a cut with antarctic phosphatase that catalyzes 
the removal of 5ʹ phosphate of the vector in order to prevent self-ligation.  The cut vector was 
resolved on 1% agarose gel in order to confirm that the cutting has been successful.  Then, the 
linearized vector of length 4900 bp was cut out and purified using QIAquick Gel Extraction Kit.  
After that, the purified XRCC4157-BamHI/XhoI fragment was ligated into the pGEX-4T-
1-BamHI/XhoI vector. The ligation reaction was transformed into competent E. coli DH5α cells 
as described in Methods and plated onto medium with ampicillin.  Single colonies were picked 
from the plates and were grown over night.  Plasmid DNA was purified using a Miniprep Kit.  
To test for plasmid DNA with the correct insert, purified plasmid DNA was digested with 
BamHI and XhoI.  The resulting DNA fragments were separated on a 1 % agarose gel (Figure 3-
3) to confirm whether the cloning of XRCC4157 into pGEX-4T-1 vector had been successful.  It 
was expected to see two bands, one band on about 500 bp and one band on about 5000 bp.  The 
results show that ten out of the twelve minipreps (lanes 1-5, 7, and 9-12) have bands on the right 
size, 504 bp and 4900 bp. Lane 6 and 8 probably contain a religated vector with no insert.  
Plasmid DNAs (from minipreps 2, 4, 9 and 11) were sent for sequencing and confirmed as 
correct (Figure 3-4). 
After that, pGEX-4T-1 - XRCC4157 plasmid was transformed in E. coli BL21 for protein 
expression to produce GST tagged XRCC4157.   The protein was produced and purified as 
described in Methods.  Then, fractions of the lysate, flow through, washes, and eluted protein 
were run on a 10% SDS-PAGE stained with coomassie blue.  A scanned image of the coomassie 
stained SDS-PAGE gel is shown in Figure 3-5.  The result from the gel analysis shows a major 
band corresponding to the molecular size of the GST- XRCC4157 protein, which is around 44 kD.  
The concentration of the protein was measured by a spectrophotometer (A280) and calculated to 
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be 2.58 mg/mL (57.3 µM).  The total amount of the purified fusion protein obtained from 1 L 
culture was 7.74 mg. 
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Figure	  3-­1:	  The	  strategy	  of	  cloning	  the	  WT	  XRCC4157	  gene	  into	  the	  pGEX-­4T-­1	  vector	  
and	  production	  of	  GST	  tagged	  XRCC4157	  protein.	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Figure 3-2: The XRCC4157 fragment and pGEX-4T-1 Vector Cut.  Lane 1: pGEX-4T-1 cut 
with BamHI and XhoI to form single band around 4900 bp.  Lane 2: XRCC4157 fragment 
amplified by PCR from pFLAG-CMV2-XRCC4336 plasmid.  The lower band on about 504 bp 
indicates the XRCC4157 constructed fragment (XRCC4 = 471 bp, BamHI = 6 bp, XhoI = 6 bp, 
stop codon = 3 bp and 6xHis = 18 bp).  The pGEX-4T-1 vector and XRCC4157 fragment were cut 
out from the gel and purified. 	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Figure 3-3: Cloning of Wild Type XRCC4157 into pGEX-4T-1 Vector. The WT XRCC4157 
fragment was cloned into pGEX-4T-1 vector.  Then, the XRCC4157 was cut out from the pGEX-
4T-1 vector with BamHI and XhoI restriction enzymes.   Two bands were formed; the upper 
band is around 4900 bp indicating the pGEX-4T-1 vector and the lower band is around 504 bp 
indicating the XRCC4157 insert.  The results show that the samples in lanes 1-5, 7, and 9-12 have 
an insert on the expected size. 	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Figure	  3-­4:	  XRCC4157	  sequence.	  Nucleotide	  1-­‐6	  is	  BamHI	  sequence.	  7-­‐477	  is	  the	  XRCC157	  sequence.	  	  479-­‐495	  is	  the	  6xHis	  sequence.	  	  496-­‐498	  is	  the	  stop	  codon	  sequence.	  	  499-­‐504	  is	  the	  XhoI	  sequence.	  
User9.16.11_G08_XC4.GXF.ab1
G S M E R K I S R I H L V S E P S I T H F L Q V S
GG ATCCATGG AGAGAAAAATAAGCAGAATCCACCTTGTTTCTGAACCCAGTATAACTCATTTTCTACAAGTATC
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S W E K T L E S G F V I T L T D G H S A W T G T V
CTTGGGAGAAAACACTGGAATCTGGTTTTGTTATTACACTTACTGATGGTCATTCAGCATGGACTGGGACAGT
80 90 100 110 120 130 140
V S E S E I S Q E A D D M A M E K G K Y V G E L R K
TTTCTGAATCAGAGATTTCCCAAGAAGCTGATGACATGGCAATGGAAAAAGGGAAATATGTTGGTGAACTGAGAA
150 160 170 180 190 200 210
K A L L S G A G P A D V Y T F N F S K E S C Y F F
AAAGCATTGTTGTCAGGAGCAGGACCAGCTGATGTATACACGTTTAATTTTTCTAAAGAGTCTTGTTATTTCTTC
220 230 240 250 260 270 280 290
F F E K N L K D V S F R L G S F N L E K V E N P A E
CTTTGAGAAAAACCTGAAAGATGTCTCATTCAGACTTGGTTCCTTCAACCTAGAGAAAGTTGAAAACCCAGCTGA
300 310 320 330 340 350 360
E V I R E L I C Y C L D T I A E N Q A K N E H L Q
AAGTCATTAGAGAACTTATTTGTTATTGCTTGGACACCATTGCAGAAAATCAAGCCAAAAATGAGCACCTGCAG
370 380 390 400 410 420 430 440
Q K E N E R L L R D W N D H H H H H H * LE
GAAAGAAAATGAAAGGCTTCTGAGAGATTGGAATGATCATCATCATCATCATCACTGACTCGAG
440 450 460 470 480 490 500
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Figure 3-5: Protein Composition of WT GST-XRCC4157 as determined by SDS-PAGE.  
10% polyacrylamide gradient gel stained with coomassie blue.  Lane 1: 30 µL of lysate was 
loaded (out of 5 mL). Lane 2: 30 µL of flow through was loaded (out of 5 mL).  Lane 3: 30 µL 
of washes (out of 20 mL).  Lane 4-9: 30 µL of different protein elutions (each elution was 1 mL). 
The results show that the samples in lanes 4-9 have the WT GST-XRCC4157 protein on the 
expected size (44 kD). 	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3.2 Cloning of Double-mutant XRCC4157 (M61R and F106E) into pGEX-4T-1 Vector and 
Production of DM GST-XRCC4157 Protein 
The purpose of producing a double-mutant XRCC4157 comprising M61R and F106E is to 
use it in the pre-clearing process during the selection.  This is to eliminate any non-specific 
peptide inhibitors that might bind to regions other than that of the XLF interface of XRCC4.  The 
two mutations at M61R and F106E were introduced directly into the WT pGEX-4T-1- 
XRCC4157 plasmid by constructing mutagenic primers and following the QuickChange site-
directed mutagenesis procedure (Figure 3-6).  Then, plasmid DNA was transformed into 
competent E. coli DH5α cells as described in Methods and plated onto medium with ampicillin.  
Single colonies were picked from the plates and were grown overnight.  Plasmid DNA was 
purified using QIAGEN Miniprep Kit. Plasmid DNA’s (from minipreps 1-8) were sent for 
sequencing and confirmed positive (Figure 3-7). 
After that, the DM pGEX-4T-1 - XRCC4157 plasmid was transformed into E. coli BL21 
for protein expression to produce GST tagged DM XRCC4157.   The protein was produced and 
purified as described in Methods.  Then, fractions of the lysate, flow through, washes, and eluted 
protein were run on a 10% SDS-PAGE stained with coomassie blue.  Ascanned image of the 
coomassie stained SDS-PAGE gel is shown in Figure 3-8.  The result from the gel analysis 
shows a band corresponding to the molecular size of the GST-XRCC4157 DM protein, which is 
around 44 kD.  The concentration of the protein was measured by a spectrophotometer (A280) 
and calculated to be 5.96 mg/mL (132 µM). The total amount of the purified fusion protein 
obtained from 1 L culture was 17.88 mg.  
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Figure 3-6: The strategy of cloning the DM XRCC4157 gene into the pGEX-4T-1 vector and 
production of GST tagged XRCC4157 protein. 
Wild Type pGEX-4T-1 - 
XRCC4157 plasmid 
Transformation of DM 
pGEX-4T-1 - XRCC4157 into 
competent E. coli cells 
Plasmid purification by 
Miniprep kit 
Sequencing To confirm that we have 
introduced the mutations 
at M61R and F106E 
successfully 
Introducing M61R and F106E mutations by using 
QuickChange site-directed mutagenesis kit 
Transformation of DM pGEX-4T-1 - 
XRCC4157 into competent E. coli cells 
for protein expression 
Ni-NTA protein Purification 
SDS - PAGE To confirm that we have 
the right protein size 
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UserB11.1.11_F08_XDM3.GXR.ab1
G S M E R K I S R I H L V S E P S I T H F L Q V S W
GGATCCATGGAGAGAAAAATAAGCAGAATCCACCTTGTTTCTGAACCCAGTATAACTCATTTTCTACAAGTATCTTG
10 20 30 40 50 60 70
W E K T L E S G F V I T L T D G H S A W T G T V S E S
GGGAGAAAACACTGGAATCTGGTTTTGTTATTACACTTACTGATGGTCATTCAGCATGGACTGGGACAGTTTCTGAAT
80 90 100 110 120 130 140 150
S E I S Q E A D D M A R E K G K Y V G E L R K A L L
TCAGAGATTTCCCAAGAAGCTGATGACATGGCAAGGGAAAAAGGGAAATATGTTGGTGAACTGAGAAAAGCATTGTTG
160 170 180 190 200 210 220 230
L S G A G P A D V Y T F N F S K E S C Y F F F E K N L
GTCAGGAGCAGGACCAGCTGATGTATACACGTTTAATTTTTCTAAAGAGTCTTGTTATTTCTTCTTTGAGAAAAACCTG
230 240 250 260 270 280 290 300
L K D V S E R L G S F N L E K V E N P A E V I R E L I
GAAAGATGTCTCAGAGAGACTTGGTTCCTTCAACCTAGAGAAAGTTGAAAACCCAGCTGAAGTCATTAGAGAACTTAT
310 320 330 340 350 360 370 380
I C Y C L D T I A E N Q A K N E H L Q K E N E R L L
TTTGTTATTGCTTGGACACCATTGCAGAAAATCAAGCCAAAAATGAGCACCTGCAGAAAGAAAATGAAAGGCTTCTG
390 400 410 420 430 440 450 460
L R D W N D H H H H H H * LE
GAGAGATTGGAATGATCATCATCATCATCATCACTGACTCGAG
470 480 490 500
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Figure	  3-­7:	  Double-­mutant	  XRCC4157	  sequence.	  Red	  circles	  indicate	  the	  sites	  of	  the	  two	  mutations	  inserted	  in	  which	  the	  Methionine	  (ATG)	  was	  mutated	  to	  Arginine	  (AGG)	  and	  the	  Phenylalanine	  (TTC)	  was	  mutated	  to	  Glutamic	  acid	  (GAG).	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Figure 3-8: Protein Composition of DM GST-XRCC4157 as determined by SDS-PAGE.  
10% polyacrylamide gradient gel stained with coomassie blue. Lanes 1-5: 30 µL of different 
protein elutions (each elution was 1.5 mL). Lane 6: 30 µL of washes (out of 20 mL). Lane 7: 30 
µL of flow through was loaded (out of 5 mL). Lane 8: 30 µL of lysate was loaded (out of 5 mL). 
The results show that the samples in lanes 1-5 have the DM GST-XRCC4157 protein on the 
expected size (44 kD). 	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3.3 Thrombin Cleavage of GST- XRCC4157 DM Protein 
We have tried to remove the GST moiety from the double-mutant GST tagged XRCC4157 
protein.  The idea is to use a non-GST tagged XRCC4157 DM during the elution step in the 
selection process.  Once the mRNA-peptide fusions are mixed with the WT GST-XRCC4157 and 
captured on magnetic glutathione beads, the reaction will be washed with the DM XRCC4157 in 
order to remove all non-specific mRNA-peptide inhibitors. This is another way to increase the 
stringency of the selection system.  
We used thrombin (GE Healthcare) to cleave the GST from double mutant XRCC4157 
protein.  Thrombin cleaves Arg-Gly bonds in specific sequences (LeuVal-Pro-Arg↓Gly-Ser).  
After incubating the thrombin with DM GST-XRCC4157 protein, different samples were removed 
at various time points and analyzed by 12% SDS-PAGE to estimate the yield, purity and extent 
of thrombin digestion.  The results show that the GST moiety was not completely removed 
(Figure 3-9).  We have tried many times to cleave the GST with different conditions but still 
large amount of protein could not be cleaved.  Therefore, we cloned the DM XRCC4157 into 
pET-32XT expression vector (see below).  
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Figure 3-9: Thrombin cleavage of GST-XRCC4157 DM as determined by SDS-PAGE.  12% 
polyacrylamide gradient gel stained with coomassie blue.  Lane 1: 25 µL (10 µg) of uncleaved 
GST-XRCC4157 before dialysis. Lane 2: 25 µL (10 µg) of uncleaved GST-XRCC4157 after an 
overnight dialysis with 1 L of 1X PBS buffer.  Lane 3-6: 10 µL (out of 230 µL total reaction) of 
the cleaved protein (1 mg) with 1 unit thrombin after 2, 4, 16 and 18 hours. Lane 7-9: 10 µL (out 
of 230 µL total reaction) of the cleaved protein with 2 units thrombin after 2, 4 and 18 hours. The 
GST molecular weight is about 26 kD and the XRCC4157 molecular weight is about 18 kD.                             	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3.4 Cloning of Double-mutant XRCC4157 (M61R and F106E) into pET-32XT Vector and 
Production of DM Thioredoxin (Trx) - XRCC4157 Protein 
We were not able to remove the GST tag from the DM GST-XRCC4157.  Therefore, we 
cloned the DM XRCC4157 into pET-32XT expression vector to produce DM XRCC4157 protein 
with Thioredoxin (Trx) tag.  The production of DM Trx-tagged XRCC4157 started by cutting 
both DM pGEX-4T-1 – XRCC4157 and pET-32XT - Smad6 MH2 domain with BamHI and XhoI 
(Figure 3-10).  Then, the cut plasmid DNA’s were resolved on 1% agarose gel in order to 
confirm that the cutting has been successful (Figure 3-11).  Then, the DM XRCC4157 fragment on 
504 bp and the pET-32XT vector on 5.9 Kp were cut out and purified using QIAquick Gel 
Extraction Kit. 
After that, the purified DM XRCC4157-BamHI/XhoI fragment was ligated into the pET-
32XT-BamHI/XhoI vector.  The ligation reaction was transformed into competent E. coli DH5α 
cells as described in Methods and plated onto medium with ampicillin.  Single colonies were 
picked from the plates and were grown overnight.  Plasmid DNA was purified using a Miniprep 
Kit.  To test for plasmid DNA with correct insert, purified DNA was digested with BamHI and 
XhoI.  The resulting DNA fragments were separated on a 1% agarose gel to confirm whether the 
cloning of XRCC4157 into pET-32XT vector had been successful (Figure 3-12).  The results 
show that eight out of the twelve minipreps (lanes 2-6, 8, 9 and 12) have bands on the right size, 
504 bp and 5.9 Kp.  Lane 1 probably contains supercoid uncut plasmid.  Lane 7 and 10 seems to 
have pET-32XT harboring the original insert (Smad6-MH2 domain).  Lane 11 contains a 
religated vector with no insert.  Minipreps 4 and 8 were sent for sequencing and confirmed 
positive. 
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After that, the DM XRCC4157 – pET-32XT plasmid was transformed in E. coli BL21 for 
protein expression to produce Thioredoxin-tagged XRCC4157 DM.   The protein was produced 
and purified as described in Methods.  Then, fractions of the lysate, flow through, washes, and 
eluted protein were run on a 10% SDS-PAGE stained with coomassie blue.  Scanned image of 
the coomassie stained SDS-PAGE gel is shown in Figure 3-13.  The result from the gel analysis 
shows a band corresponds to the molecular size of the Trx- XRCC4157 protein, which is around 
37 Kd.  The concentration of the protein was measured by a spectrophotometer (A280) and 
calculated to be 5.49 mg/ml (149.5 µM). The total amount of the purified fusion protein obtained 
from 1 L culture was 21.96 mg. 
 
	   51	  
 
Figure 3-10: The strategy of cloning the DM XRCC4157 gene into the pET-32XT vector and 
production of Thioredoxin tagged XRCC4157 protein. 
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Figure 3-11: DNA segment encoding DM XRCC4157 (M61R and F106E) was cut out from 
the pGEX-4T-1 vector and the pET-32XT was linearized.  Lane 1:  The DM XRCC4157 is cut 
out from the pGEX-4T-1 vector with BamHI and XhoI.  Two bands were formed; the lower band 
on about 504 bp indicates the DM XRCC4157 insert while the upper on 4900 bp indicates the rest 
of pGEX-4T-1 vector.  Lane 2: to form single band around 4900 bp.  Lane 2: Removal of Smad6 
MH2 domain insert from pET-32XT vector by cutting the DNA plasmid with BamHI and XhoI.  
Two bands were formed; the upper band on 5900 bp indicates the pET-32XT vector while the 
lower band on 550 bp indicates the Smad6 MH2 domain insert. The DM XRCC4157 fragment and 
the pET-32XT vector were cut out from the gel and purified. 	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Figure 3-12: Cloning of Double-Mutant XRCC4157 (M61R and F106E) into pET-32XT 
Vector. The DM XRCC4157 fragment was cloned into pET-32XT vector.  Then, the XRCC4157 
was cut out from the pET-32XT vector with BamHI and XhoI restriction enzymes. Two bands 
were formed; the upper band is around 5900 bp indicating the pET-32XT vector and the lower 
band is around 504 bp indicating the DM XRCC4157 insert.  The results show that the samples 
lanes 2-6, 8, 9 and 12 have an insert on the expected size.	  
	   54	  
 
Figure 3-13: Purification of DM Trx-XRCC4157 protein as determined by SDS-PAGE. 10% 
polyacrylamide gradient gel stained with coomassie blue.  Lane 1: 25 µL of lysate was loaded 
(out of 10 mL). Lane 2: 25 µL of flow through was loaded (out of 10 mL).  Lane 3: 30 µL of 
washes (out of 20 mL).  Lane 4-9: 25 µL of different protein elutions (each elution was 2 mL). 
The results show that the samaples in lanes 4-9 have the DM Trx-XRCC4157 protein on the 
expected size (37 Kd). 	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3.5 mRNA Display and In Vitro Selection 
3.5.1 Preparation of the DNA libraries 
The five DNA libraries have been synthesized in an innovative way such that they can 
produce peptide libraries that have both building block and large scaffold diversity.  The 
structure of each DNA library was described in Methods.  In order to ensure that the libraries 
were synthesized as designed, the composition and nucleotides distribution of the DNA libraries 
were verified.  Each library was first PCR amplified and resolved on 2% agarose gel (Figure 3-
14).  As expected a band appears around 150 bp that corresponds to the size of the DNA 
template.  Then, each library was gel purified by QIAquick Gel Extraction Kit and ligated into 
the StrataClone vector.  The ligated reaction was transformed into StrataClone SoloPack 
competent cells and plated onto medium with kanamycin.  Ninety-six single colonies were 
picked from the plates and sent for sequencing.  
The sequences of the libraries were analyzed by using Bio-Edit software.  As shown in 
Figure 3-15, there are two fixed cysteines; one at the N-terminus and another one after 2, 4, 6, 8 
or 10 random amino acids, as expected.  In the random region of our libraries we used NNS 
codons in which N denotes A, T, C, or G, and S denotes G, or C.  The benefit of using NNS 
codons is to increase the diversity of the libraries and to reduce stop codon usage, which will 
improve the percentage of library members without stop codons to 62% compare to NNN 
codons.   Therefore, once would expect for an ideal library that each library will have 25% 
distribution of each nucleotide in the NN part and 50% distribution of either G or C in the S part 
of the NNS codon.  As it is illustrated in Figure 3-16, the A, T, C, and G in the NN part are 
almost equally distributed in each library.  Also, there is almost 50% distribution of G and C in 
the S part.  The presence of A or T in the S part may be due to mutation or frameshift.   
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Figure 3-14: DNA library on 2% agarose gel.  Lane 1: CX2CX4 DNA library. Lane 2: 
CX4CX8 DNA library. Lane 3: CX6CX6 DNA library. Lane 4: CX8CX4 DNA library. Lane 5: 
CX10CX2 DNA library. Lane 6: no template.  The upper bands were cut and gel purified. 	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Figure 3-15: DNA libraries sequence.  Each library was PCR-amplified and sample clones 
were sequenced.  The predicted amino acid sequence from each clone is shown. 	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 A 
B 
Figure 3-16: Distribution of the nucleotides in the NNS codon. Panel A shows the distribution 
of A, T, C, and G in the NN part.  Panel B shows the distribution of the G and C in the S part.   	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3.5.2 Small Scale of In Vitro Transcription and Translation 
The transcription of the five DNA templates was carried out to produce five mRNA 
libraries.   The transcription reaction of each template was loaded on urea PAGE in order to 
separate the mRNA from the DNA (Figure 3-17).   The mRNA band was visualized by UV 
shadowing and the band cut out of the gel.  The mRNA was eluted and ethanol precipitated and 
the concentration of each library was measured by spectrophotometer (A260).   
 Following transcription, a small scale of an in vitro translation was carried out for each 
library.   The purpose of this is to ensure that our mRNA templates are translatable.  We used the 
DYKM template as a standard mRNA template.  DYKM was originally designed to test analogs 
of 4 of the natural amino acids (Hartman et al., 2007).  It has a translatable region of 4 amino 
acids (D, Y, K, and M) and 6xHis tag in the c-terminus.  We are using DYKM template here to 
compare the translation efficiency of our mRNA libraries to it.  The translation reactions were 
carried out with 35S-methionine as the N-terminal residue.  The average amount of the translated 
peptides was about 0.3 pmole (Figure 4-18).  This is lower than what we were expecting; 
nevertheless, this indicates that the mRNA templates can be translated.  Also, we will use large 
scale of in vitro translation reaction, which will increase the amount of translated peptides. 
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LD  
Figure 3-17: Separation of the mRNA on a 6% PAGE/urea gel. The 1 mL transcription 
reaction of CX4CX8 library was loaded on the gel without adding loading dye.  The mRNA 
band (upper band) was visualized by UV shadowing.  The lower band shows the separated DNA.  
10 µL of bromophenol loading dye (LD) was loaded.  	  
mRNA  
DNA 
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Figure 3-18: In vitro translation.  A final translation reaction of 50 µL was carried out for each 
mRNA library showing that they are translatable.  	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3.5.3 In Vitro Selection 
3.5.3.1 First Round 
The formation of mRNA display natural cyclic peptide library started by the transcription 
of the five DNA templates that encode peptides with 15 random amino acids interspersed with 
two cysteine residues.  Following transcription, the five mRNA libraries were combined together 
to a final concentration of 2 µM and photo cross-linked to a 3ʹ′-puromycin oligonucleotide.  
Then, the combined mRNA libraries were translated on a 5 mL translation scale in a completely 
reconstituted translation system with 20 natural amino acids.  After that, mRNA peptide fusions 
were immobilized on an oligo-dT column and cyclized using dibromoxylene.   These two 
processes were performed to remove peptides that are not conjugated to their mRNAs, to remove 
mRNAs that were not photo crosslinked by psoralen and to produce cyclic mRNA-peptide 
fusions.  Then, the pmole amount of the mRNA-peptide fusions was calculated based on the 
scintillation counts of the 35S-Met to be 7 pmole.  After that, the peptide-fusions were reverse 
transcribed to create double-stranded template and to eliminate any unwanted RNA secondary 
structures and render the nucleic acid portion of the fusion more stable.  The percentage of the 
peptide fusions recovered after this step was 37% (2.6 pmole).  Then, the mRNA-peptide fusions 
were purified by Ni-NTA purification.  Ni-NTA binds to the C-terminal 6xHis tag incorporated 
into the peptide in order to remove the truncated mRNA peptide fusions.  The percentage of the 
peptide fusions recovered after Ni-NTA was 45% (1.18 pmole).  The eluents with high counts 
were collected and dialyzed overnight at 4°C in 1X selection buffer.  The overnight dialyzed 
peptide mRNA-fusions was collected and the percentage calculated to be 122% (1.44 pmole), 
which is about a trillion peptide variants that are going to the selection procedure. 
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In the selection step of the first round, we first incubated our library with GST protein on 
magnetic beads (pre-clear).  This is to remove all non-specific peptide inhibitors that bind to the 
GST or glutathione magnetic beads.  The mRNA-peptide fusions in the flow through and washes 
were counted to find that 53% (0.76 pmole) of the peptide fusions was recovered.  Then, the flow 
through and washes with high counts were collected and bound to WT GST-tagged XRCC4157 
fragment.  This fragment includes the complete head domain known to contain the XLF interface 
but lacks the C-terminal DNA ligase IV-binding region that could interact with the mRNA 
component of our mRNA-peptide fusions.  Those peptides that bound to WT GST-XRCC4157 
were captured on glutathione magnetic beads.  Then, the beads were washed and suspended in 
selection buffer and the percentage of the 35S-labeled peptides bound to the resin was measured 
to be 2.1% (0.03 pmole).  The DNA-mRNA duplex fused to the XRCC4-captured peptides was 
amplified by PCR. 
 
3.5.3.2 Second round 
 The resulting DNA from the first round was in vitro transcribed and then new mRNA-
peptide fusions were formed.  However, from the second round and subsequent rounds the 
translation scale is going to be 500 µL.  Also, for the second and third rounds, we used GST 
protein on glutathione magnetic beads for pre-clearing.  The amount of the mRNA-peptide 
fusions after in vitro translation, oligo dT purification and cylizatioin was 2.75 pmole.  The 
percentage recovered after reverse transcription was 51% (1.4 pmole), after Ni-NTA was 52% 
(0.73 pmole), after dialysis was 47% (0.35 pmole) and after pre-clearing with GST protein was 
95% (0.33 pmole).  The percentage peptide fusions that bound WT GST-XRCC4157 and captured 
on glutathione magnetic beads was 1.14% (0.004 pmole).   
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3.5.3.3 Third round 
 The amount of the mRNA-peptide fusions after in vitro translation, oligo dT purification 
and cylization was 6.97 pmole.  The percentage recovered after reverse transcription was 29% (2 
pmole), after Ni-NTA was 56% (1.11 pmole), after dialysis was 49% (0.55 pmole) and after pre-
clearing with GST protein was 134% (0.73 pmole).  The percentage of the peptide fusions that 
bound to WT GST-XRCC4157 and captured on glutathione magnetic beads was 2% (0.011 
pmole).   
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Figure 3-20: Recovery of the mRNA-peptide fusions during the first three rounds of in vitro 
selection process. Panel A shows the percentage of the mRNA-peptide fusions recovered after 
purifications, dialysis, pre-clearing and incubation with GST-XRCC4157 protein during the first 
three rounds.  Panel B shows only the percentage of the mRNA-peptide fusions recovered after 
incubation with the GST-XRCC4157 protein at each round of selection. 
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Figure 3-21: Scheme of mRNA Display and in vitro selection for XRCC4157. 
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IV. DISCUSSION AND FUTURE DIRECTION 
 
4.1 Therapeutic potential of suppressing DSB repair 
Induction of DNA damage by a radio- or chemotherapeutic agent is still a key element in 
cancer therapy.   However, the dose of DNA damaging agent that can be delivered to the cancer 
cells is limited due to the toxic side effects produced by such agents.  Exposure to cytotoxic 
agents also results in the activation of accurate or inaccurate DNA repair mechanisms that allow 
the survival of cancer cells leading to inadequate tumor response to radio- or chemotherapy 
(Bolderson et al., 2009).  Therefore, targeting the DNA repair mechanisms that are required for 
cancer cell survival will increase the efficiency of radio- or chemotherapy.  Furthermore, since 
cancer cells often have disrupted DNA damage and repair responses, they may be more 
susceptible than normal cells to interference with normal repair mechanisms. 
The majority of ionizing radiation-induced DSBs are repaired by NHEJ in mammalian 
cells, which has raised the possibility of directly targeting the NHEJ proteins and their 
interactions for the purpose of radiosensitization of tumor cells.  DNA-PK has been shown to be 
a good target for radiosensitization of tumor cells, in that cells deficient in Ku70/80 or the DNA-
PKcs are sensitive to DSBs induced by IR. The use of NU7441, a DNA-PK inhibitor, has shown 
an increase in the radiosensitivity of different cell lines and in xenograft models in preclinical 
trials (Zhao et al., 2006).  However, inhibitors of DNA-PK will also interfere with its roles in 
telomere maintenance (Gilley et al., 2001; Goytisolo et al., 2001) and immune functions (W. Chu 
et al., 2000; Dragoi et al., 2005).  Therefore, finding a more selective inhibitor is required. 
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Inhibition of XRCC4 is a particularly attractive target for overcoming tumor 
radioresistance because its only known function is NHEJ (Schaue & McBride, 2005).  Also, it 
has been shown that breast tumor cells can be radiosensitized by adenovirus-mediated 
overexpression of a fragment of XRCC4 that binds ligase IV but does not support NHEJ (Jones 
et al., 2005).  In addition, the interaction between XRCC4 and XLF should be a much more 
susceptible target for radiosensitization because, whereas XRCC4 and ligase IV form a tight 
complex in cells, the XRCC4-XLF interaction is transient.  With any radiosensitizer, there will 
undoubtedly be some sensitization of normal tissues, and whether inhibition of NHEJ will 
ultimately improve therapeutic index is difficult to predict and will only be determined by future 
preclinical and clinical studies.  However, as many breast tumor cells have partial deficiency in 
HRR and/or upregulated NHEJ (Gudmundsdottir & Ashworth, 2006; Nagaraju & Scully, 2007; 
H. Wang et al., 2001; Zhuang et al., 2006), raising the possibility that they may indeed be 
sensitized more than surrounding tissue when NHEJ is suppressed.  Furthermore, when breast 
tumors treated with radiation metastasize, the subsequent tumors are often highly radioresistant 
due to upregulation of these downstream pathways (Johnston et al., 2006; Das et al., 2007) 
raising the possibility that the therapeutic index with metastasized tumors could be even greater.  
Therefore, in order to inhibit the interaction between XRCC4 and XLF, a powerful 
technique such as mRNA display should be implemented.  This technique has been used to find 
inhibitors of protein-protein and protein-ligand interactions (Schilppe et al., 2012; Getmanova et 
al., 2006).  We chose mRNA display over the other selection techniques available because it 
possesses several advantages.  For example, the presence of the covalent bond between the 
peptide and mRNA makes it highly stable compare to a non-covalent bond linkage in other 
techniques such as the ribosome display (Hui & Rihe, 2011).  Therefore, in mRNA display the 
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selection process can be performed under stringent conditions in order to optimize the selection 
of specific binders from non-specific ones.  Another advantage of mRNA display is the ability of 
producing large libraries of different unique sequences.  mRNA display is totally an in vitro 
selection technique that can produce as many as 1012-1014 unique sequences while other 
techniques that rely on an in vivo process have limitation such as phage display that produces 
diverse sequences of up to 1010 only.  Other advantage of mRNA display includes the easy 
removal of abundant sequences from the starting library increasing the chance of selection non-
abundant sequences.   
Therefore, we produced WT GST-XRCC4157 protein in order to use it for the selection of 
the peptide inhibitors of the XRCC4/XLF interaction.  We used truncated XRCC4 because the 
interaction between XRCC4 and XLF has been shown to be through the head domains (Ropars et 
al., 2011; Malivert et al., 2010).  We also produced DM GST- XRCC4157 comprising M61R and 
F106E; M61 and F106 are two residues that are required for the interaction between XRCC4 and 
XLF. Production of DM GST-XRCC4157 protein is to use it in a pre-clearing step to eliminate 
any non-specific peptide inhibitors that might bind to regions other than the XLF interface of 
XRCC4. We have conducted circular dichroism (CD) study to see if the mutated XRCC4 protein 
is folded properly.  As shown in Figure 4-1, the DM XRCC4157 protein has similar CD spectrum 
to that of the WT protein suggesting that the mutant protein is folded correctly and therefore will 
be effective in removing peptides that bind elsewhere on XRCC4.  We also produced DM Trx-
XRCC4157 protein to increase the stringency of the selection system.  The DM Trx-XRCC4157 
will be used during the elution step in the selection process.   
Five DNA libraries have been synthesized and we have sequenced sample clones of each 
library to find that they have the sequences as they were designed.  We have finished three 
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rounds of the in vitro selection of the XRCC4/XLF interaction inhibitors. About a trillion 
mRNA-peptide variants went to the selection in the first round.  We were expecting about 10 
trillions unique peptide fusions to start the selection; nevertheless, the amount we obtained 
should be sufficient to find selective inhibitors.  The average number of unique molecules 
produced by an mRNA display technique is about 1012-1014 unique sequences.  The percentage 
of the mRNA-peptide fusions that bound to the XRCC4157 after the first round was 2.1% of those 
peptide fusions collected after pre-clearing.  This is a good result since abundant sequences of 
non-selective inhibitors were removed leaving the selective ones to go for the next round.  The 
recovery after the second round was 1.14%.  The decrease in the percentage of the peptide 
fusions recovered after the second round may be due the fact that we reduced the amount of the 
translation reaction from 5 mL in the first round to 500 µL in the second round.  The third round 
had a recovery of 2%.  Even though the recovery is not yet increasing significantly, we would 
expect to have a higher percentage of peptide fusions recovered after subsequent rounds.  
Moreover, the progression in recovery from the pre-clearing step in rounds 2-3 suggest that those 
peptides bind to the GST tag are in fact being removed by pre-clearing. 
 
4.2 Future Direction 
The selection process will continue for several rounds until the percentage of the mRNA-
peptide fusions eluted begins to plateau signifying that enrichment has stopped.  The DNA from 
that round will be cloned into vector and sequenced to determine the natural peptide motifs that 
bound to the XRCC4/XLF interface. Our lab experience suggests that this process will take 6-8 
rounds and will lead to 6-8 families of function natural cyclic peptides.  We will choose 1 or 2 
peptides representative from each of the families for further analysis (Figure 4-2).  To test these 
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peptides, we will use highly sensitive NHEJ assays (Akopiants et al., 2009).  We expect that 50 
pmoles of each peptide will be enough to do several replicate in vitro assays with that peptide.   
Once the candidate peptides have been ranked with respect to potency in inhibiting NHEJ 
in extracts, 4-5 peptides will be chosen for evaluation of cytotoxicity.  Typically, these will be 
the most potent inhibitors, but with some preference for diversity in primary structure as well.  
Each peptide will be synthesized on a mmole scale by microwave-enhanced Fmoc-based solid 
phase peptide synthesis and purified by HPLC.  During the course of the synthesis we will 
append a C-terminal cell-penetrating peptide sequence (Arg9), which will enable cell 
permeability of the peptides for the assays in cell culture (Goun et al., 2006).   
Because the ultimate clinical use of the peptides would likely be for treatment of tumors 
resistant to radiotherapy, the peptides will be ranked according to their ability to radiosensitize 
MCF-7/HER2 cells.  This line is a derivative of MCF-7 that has been engineered to overexpress 
HER2, and consequently is resistant to both radiation and chemotherapeutic drugs (Liang et al., 
2003).  Clonogenic survival assays will be performed and one or two peptides will be chosen for 
further studies in multiple cell lines.  For example, they will be examined in MDA-MB-231-BR 
cells, a clone derived from MDA-MB-231 cells that specifically metastasized to brain in mice 
(Yoneda et al., 2001), as well as in 4T1 cells, a murine mammary tumor that metastasizes to 
lung.  These lines are chosen, in part, in anticipation of future preclinical studies of metastatic 
disease in mice. 
Also, we would like to evaluate the modes of radiation-induced cell death following 
irradiation in the presence or absence of peptide inhibitors, specifically, senescence (β-
galactosidase staining, cell morphology), apoptosis (fluorescent DNA end-labeling (TUNEL) 
and prodpidium iodide flow cytometry), mitotic catastrophe (formation of micronuclei in 
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binucleated cells) and autophagy (acridine orange staining, LC3-1 cleavage by western blot, and 
electron microscopy) (Di et al., 2009; Klionsky et al., 2008).  
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Figure 4-1: CD spectra of wild type and double-mutant GST-XRCC4157. The similarity in 
the UV spectra between the wild type (blue line) and double-mutant (pink line) GST-XRCC4157 
indicates that the double mutant is folded correctly. 
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Figure	   4-­2:	   Overall	   scheme	   for	   synthesis,	   selection	   and	   evaluation	   of	   XRCC4/XLF	  
interaction	  inhibitors.	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